Accessibility statement

Estimating the cost-effectiveness of strategies for the initial management of potential infection in advanced HIV

Thursday 18 April 2019, 12.15PM to - 1.15pm

Speaker(s): Edward Cox, CHE, University of York

Abstract: Many HIV-positive individuals in Africa have advanced disease (CD4 <200 cells/mm3) when initiating antiretroviral therapy (ART) and have high risks of opportunistic infection and death. The REALITY trial found that an enhanced-prophylaxis package including fluconazole reduced mortality by 27% in individuals with CD4 <100 cells/mm3. We investigated the cost-effectiveness of the REALITY enhanced-prophylaxis package versus other strategies, including those based on cryptococcal antigen (CrAg) testing. A decision analytic model was developed to estimate the cost-effectiveness of six management strategies in patients initiating ART with advanced HIV. The model estimated costs and quality-adjusted life-years (QALY) over 48 weeks based on a competing-risk mortality approach.
In this seminar I will provide some background information on advanced HIV in Africa and an overview of the modelling, cost-effectiveness analyses and exploratory work conducted as part of an economic evaluation of management strategies based on the REALITY trial.

Location: The Professor Alan Maynard Auditorium A/RC/014

Who to contact

For more information on these seminars, contact:
Alfredo Palacios
Shainur Premji

If you are not a member of University of York staff and are interested in attending a seminar, please contact 
so that we can ensure we have sufficient space

Economic evaluation seminar dates

  • Tuesday 28 November 2023
  • Thursday 14 December 2023